Skip to content

Disc Medicine IRON Cash Provided by (Used in) Investing Activity, Including Discontinued Operation

Cash Provided by (Used in) Investing Activity, Including Discontinued Operation at other companies

Repligen logo
RepligenRGEN
-$3.99M+94.6%
Travel + Leisure logo
Travel + LeisureTNL
-$18M+18.2%
Unifirst logo
UnifirstUNF
-$39.45M-32.5%
PennyMac Financial Services, Inc. logo
PennyMac Financial Services, Inc.PFSI
-$144.53M-576%
Envista Holdings Corporation logo
Envista Holdings CorporationNVST
-$68.9M-683%
LKQ logo
LKQLKQ
-$42M-191%

Other financials

Income statement

See full
Operating income-$69.5M-74.0%
Net income-$63.5M-86.3%
EPS (diluted)-$1.65-61.8%

Balance sheet

See full
Cash & equivalents$88.9M-27.5%
Total debt$31.1M+1.4%
Total equity$688.4M+4.3%
Total assets$750.2M+5.8%

Cash flow

See full
Operating cash flow-$62.2M-50.4%
CapEx--100%
Free cash flow-$62.2M-47.4%

Valuation

See full
Market cap$2.69B+42.2%
Enterprise value$2.63B+46.7%

Returns & leverage

See full
Return on equity-35.8%+41.3pp
Debt / equity0.0×
Current ratio24×-13.6×

Where this comes from

Reported directly by Disc Medicine in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Disc Medicine’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Disc Medicine's cash provided by (used in) investing activity, including discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Disc Medicine's cash provided by (used in) investing activity, including discontinued operation?
Disc Medicine (IRON) reported cash provided by (used in) investing activity, including discontinued operation of $58.31M in Q1 2026.
How has Disc Medicine's cash provided by (used in) investing activity, including discontinued operation changed year-over-year?
Disc Medicine's cash provided by (used in) investing activity, including discontinued operation increased by 121.4% year-over-year, from -$272.63M to $58.31M.
What is the long-term trend for Disc Medicine's cash provided by (used in) investing activity, including discontinued operation?
Over 2 years (2022 to 2024), Disc Medicine's cash provided by (used in) investing activity, including discontinued operation has grown at a 4300.0% compound annual growth rate (CAGR), from -$151K to -$292.33M.
What does cash provided by (used in) investing activity, including discontinued operation mean?
The total net cash flow resulting from all investing activities, including capital expenditures, acquisitions, and the purchase or sale of securities. It serves as a primary indicator of how much capital the company is reinvesting into its long-term growth and asset base.